Pharmicell (005690.KS) traded down -1.08 % during a 24 hours period ending at 07:30 PM Central Europe on Monday 26th. One Pharmicell stock can currently be bought for about KRW 9,600 on popular exchanges. Current supply of Pharmicell stocks is 60 mn. Pharmicell has a current market capitalization of KRW 604.2 bn and approximately KRW 4.6 bn worth of Pharmicell was traded on exchanges in the last 24 hours. Since last month end, Pharmicell has traded -17.86 % down. Simple moving average of last 200 days is at KRW 13,890.05. The highest price of past 52 weeks was recorded at KRW 21,150 on 05/04/2026. 52 weeks low was at KRW 8,140 on 07/30/2026.
Here is how related stocks have performed in the past 24 hours:
Boryung (003850.KS) traded down -1.64 % and now trades at KRW 8,300. Boryung has a market capitalisation of KRW 705 bn. Boryung has a current price to earnings ratio of 5.74.
Hanwha General Insurance (000370.KS) traded down -1.6 % and now trades at KRW 6,040. Current market capitalisation for Hanwha General Insurance is KRW 711.1 bn. Current price/earnings ratio for Hanwha General Insurance is 3.54.
Innocean Worldwide (214320.KS) traded down -1.73 % and now trades at KRW 17,270. Innocean Worldwide has a market capitalisation of KRW 704.8 bn. Innocean Worldwide has a current price to earnings ratio of 5.67.
About Pharmicell
Pharmicell Co., Ltd., a biopharmaceutical company, specializes in developing and selling stem cell drugs globally. The company operates through two divisions: Biopharmaceutical Business and Biochemical Business. Their product Cellgram-AMI, manufactured using autologous bone marrow-derived mesenchymal stem cells, enhances the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company’s other products in development include Cellgram_IS and Cellgram_SCI, brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia, as well as dendritic cell products, including Cellgram_DC, a cancer drug. Additionally, the company produces intermediates of raw material medicines such as nucleosides, mPEGs, and HDP-tosylates; and phosphorus-based flame retardants. Twelve, a stem cell bank, and cell culture media cosmetics are among their other ventures. Founded in 1968 and located in Seoul, South Korea, Pharmicell Co., Ltd. is committed to making a significant impact in the healthcare industry through its cutting-edge research and development in the field of stem cells.